Funding opportunities
2,862 live opportunities from Grants.gov, NIH, NSF, and more.
AI & Machine LearningAgriculture & Food ScienceBiomedical & HealthBiology & Life SciencesChemistry & MaterialsClimate & EnvironmentCybersecurity & ITDefense & SecurityEconomics & BusinessEducation & WorkforceEnergy & SustainabilityEngineeringHumanities & ArtsInfrastructure & TransportationMathematics & StatisticsPhysics & AstronomyPublic HealthSmall Business (SBIR/STTR)Social Sciences & PolicySpace & AerospaceVeterinary & Animal ScienceWater & Oceans
- Role of cellular physical interactions in pancreatic cancer progressionNational Cancer InstitutePA-25-301 closes 5/31/2031up to $567,264activenih
- Optimization of a novel and effective antiviral agent targeting Zika NS4BNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $627,625activenih
- Cardiorespiratory and autonomic impacts of coolants in e-cigarette aerosolsNational Heart Lung and Blood InstituteRFA-OD-25-001 closes 5/31/2031up to $782,293activenih
- Increasing Lung Cancer Screening Uptake Among High-Risk Emergency Department PatientsNational Cancer InstitutePA-25-172 closes 5/31/2031up to $345,413activenih
- Th17 plasticity in rheumatoid arthritisNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $740,319activenih
- FIRE-PF: Developing and Testing a Trauma-Informed Alcohol Intervention to Enhance Mental Health in FirefightersNational Institute on Alcohol Abuse and AlcoholismPA-24-184 closes 5/31/2031up to $188,549activenih
- NeuroASCENT- Advancing Science through Career Enhancement and Neuroscience TrainingNational Institute of Neurological Disorders and StrokePAR-23-178 closes 5/31/2031up to $269,998activenih
- Factory-treated, long-lasting permethrin baby wraps for the prevention of malaria: A phase III randomized controlled trialNational Institute of Allergy and Infectious DiseasesPA-25-305 closes 5/31/2031up to $1,235,114activenih
- Antibody-guided design of a human astrovirus vaccineNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $919,605activenih
- Cross-Tissue Multi-Omic Predictors of Allergic Disease Development and Progression in Early LifeNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $1,625,664activenih
- Delineating the role of TREM2 in chronic pancreatitisNational Cancer InstitutePA-25-301 closes 5/31/2031up to $374,006activenih
- Deciphering the Gating Mechanism of Intraflagellar Transport in Trypanosoma bruceiNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $718,028activenih
- Identification and inhibition of the novel downstream effectors of mutant Ras for mutant Ras-driven cancer targetingNational Cancer InstitutePA-25-301 closes 5/31/2031up to $693,403activenih
- Dietary and Microbial Strategies to Suppress Antibiotic-Induced AMR in the Gut MicrobiomeNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $847,217activenih
- Prospective Detection and Monitoring of NF1 peripheral nerve sheath tumors using cell-free DNANational Cancer InstitutePA-25-301 closes 5/31/2031up to $688,661activenih
- A Randomized Control Trial of a Scalable Parenting Program to support Candidate Brain Pathways, Autonomic Regulation, and Socio-Emotional Development in Preterm InfantsEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentPA-25-305 closes 5/31/2031up to $597,736activenih
- Enhancing Orthographic Communication and Literacy Outcomes for AAC Users: Investigating Effective Instructional StrategiesNational Institute on Deafness and Other Communication DisordersPA-25-303 closes 5/31/2031up to $766,451activenih
- EMT en Español para el Autismo Early Caregiver-Mediated Communication Intervention for Latino and Spanish-speaking young children with ASDNational Institute on Deafness and Other Communication DisordersRFA-DC-24-007 closes 5/31/2031up to $677,188activenih
- PbViVac: readying an effective first-generation vaccine for P. vivax malariaNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $824,264activenih
- Computational prediction of anti-cancer drug metabolizing enzymes in the human microbiomeNational Cancer InstitutePA-25-301 closes 5/31/2031up to $747,790activenih
- Maternal RSV Vaccine Durability and Infant Protection Across Multiple PregnanciesNational Institute of Allergy and Infectious DiseasesPA-25-301 closes 5/31/2031up to $802,421activenih
- Mentoring Patient-Oriented Research in the Evaluation of Novel Diagnostics for People With Advanced HIV DiseaseNational Institute of Allergy and Infectious DiseasesPA-24-188 closes 5/31/2031up to $220,485activenih
- Understanding inflammatory cell death as a driver of VEXAS pathogenesisNational Cancer InstitutePA-24-182 closes 5/31/2031up to $294,451activenih
- Neutralizing and FcR-mediating antibody specificities and function in control of HHV-8 infectionNational Institute of Allergy and Infectious DiseasesPAR-23-073 closes 5/31/2031up to $211,008activenih
- Development of Genomic Risk Prediction Models for T-cell MalignanciesNational Cancer InstitutePA-24-182 closes 5/31/2031up to $276,545activenih